

# Index

<sup>11</sup>C Methionine, 78  
<sup>131</sup>I-Mov, 18, 79  
<sup>131</sup>I-trastuzumab, 80  
<sup>177</sup>Lu, 81  
<sup>18</sup>F-FDG PET/CT, 74  
<sup>18</sup>FLT, 78  
<sup>195</sup>Pt-Cisplatinum, 79  
<sup>211</sup>At, 81  
<sup>68</sup>Ga Pentixafor, 78  
<sup>68</sup>Ga-FAPI, 78  
<sup>99m</sup>Tc/<sup>188</sup>Re-FAPI, 81  
<sup>99m</sup>Tc-MIBI, 80

## A

Absent in melanoma, 2, 62  
Acellular components of  
    malignant ascites, 49  
Adjuvant chemotherapy, 13  
Adult granulosa cell tumor, 7  
AGO score, 92  
AIM2, 62  
Annular tubule, 8  
Antiangiogenic agents, 96  
Antigens, 107, 112  
Aromatase inhibitors, 15  
Ascites, 27, 43

## B

BEP regimen, 13  
Borderline Brenner tumors, 11  
Borderline tumors, 10

## C

Cathepsins, 59

Cellular components of  
    malignant ascites, 47  
Cervical cancer, 114  
Chemoresistance, 27  
Chemotherapy, 72, 93, 94  
Classification, 45  
Clinical management, 12, 14, 15  
Clinical trials, 91, 96  
Cyto reduction, 88

## D

Diagnosis, 70  
Dysgerminoma, 2

## E

Embryonal carcinoma, 3  
Embryonic germ layers, 4  
Endometrial cancer, 111  
Endometrioid borderline  
    tumors, 11  
Epithelial ovarian  
    carcinoma, 9, 15

## F

Fertility-sparing surgery, 14  
Fibroma, 5  
Fibrosarcoma, 6

## G

GDSM, 62  
Gonadoblastoma, 2  
Gynecologic malignancies, 105

**H**

Hematopoietic cell transplantation, 13  
Heterozygosity, 8  
High grade serous ovarian cancer, 87  
High-grade serous carcinomas, 28  
Hyperthermic intraperitoneal chemotherapy, 92

**I**

Immature teratoma, 4  
Immune cells, 49  
Immunotherapy, 97, 105  
Indole-amine 2,3 dioxygenase, 111  
Inflammasomes, 57  
Inflammation, 59  
Interleukins, 59

**J**

Javelin Medley trial, 110  
Juvenile granulosa cell tumor, 7

**K**

Keratin, 9  
Kynurenines, 111

**L**

Leydig cell tumor, 6  
Liquid tumor microenvironment, 43  
Low grade serous carcinoma, 12

**M**

Malignant ascites, 27  
Management, 30, 87  
Microenvironment, 29  
Minimally invasive surgery, 14

Molecular imaging, 69  
Monitoring response to therapy, 75  
Morphological imaging, 73  
Mucinous borderline tumors, 11  
Mucinous carcinomas, 46

**N**

New therapeutic agents, 93  
NLRP3, 60  
Non-gestational choriocarcinoma, 3  
Nuclear medicine, 69

**O**

Oncolytic, 108  
Origins of ovarian tumors, 44  
Ovarian cancer, 27  
Ovarian germ cell tumors, 2, 12  
Ovarian sex cord-stromal tumors, 14  
Ovarian teratomas, 4

**P**

PARP inhibitors, 96  
Personalized medicine, 33  
Peutz Jeghers syndrome, 8  
Platinum resistance, 90  
Platinum-resistant disease, 93  
Platinum-sensitive, 91, 94  
Prevention, 71

**Q**

Quality of life, 91, 99

**R**

Radiotherapy, 77, 97  
Rare ovarian tumors, 1  
Recurrent, 73, 87

Resistant or refractory recurrence, 89  
Restaging, 76  
Risk factors, 70

## S

Screening, 71  
Secondary cytoreduction surgery, 90  
Semi sensitive recurrence, 89  
Sensitive recurrence, 89  
Seromucinous borderline tumors, 11  
Serous borderline tumors, 10  
Sertoli cell tumor, 7  
Sertoli-Leydig cell tumor, 8  
Sex cord-stromal tumors, 5, 8  
Staging, 74  
Steroid cell tumor, 6  
Stromal cells, 48  
Surgery after the first recurrence, 92  
Surgery for first relapse, 90  
Surgery, 72  
Surgical management, 15  
Suspected recurrence, 76

## T

Teratoma, 4  
Tertiary cytoreductive surgery, 92  
Thecoma, 6  
Theranostics, 69  
Time to recurrence, 88

TIP regimen, 13  
Transcoelomic dissemination, 28  
Translational research, 32  
Treatment for recurrence, 89  
Treatment options, 94  
Treatment response evaluation, 77  
Treatment, 72, 105  
Tumor microenvironment, 49  
Tumor recurrence, 13  
Tumor-associated macrophages, 49

## U

Ultrasonography, 71  
Upfront surgery, 88  
Urinary tract, 71

## V

VAC regimen, 13  
Vaccines, 107, 112, 114  
Virotherapy, 108  
Vulvar cancer, 117

## W

Wilms tumor gene product, 45  
World Health Organization, 44

## Y

Yolk sac tumor, 2

